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Patients’ readiness to start highly active antiretroviral
treatment for HIV
Hirut T Gebrekristos, Koleka P Mlisana, Quarraisha Abdool Karim
Assessing whether patients are ready to start antiretroviral treatment may improve HIV prevention
and treatment outcomes
Initiatives to increase access to antiretroviral treatment
in resource constrained settings are growing, but the
scale and magnitude of the HIV epidemic in these set-
tings raises a number of operational and ethical
challenges. Most people infected with HIV are unaware
of their status, and people who are aware of their status
fear stigmatisation and discrimination. Key themes
about access to treatment include who gets treatment,
when is the best time to start treatment, and how to
ensure therapeutic success.
Numerous guidelines for treatment have been
developed nationally and internationally. One concern
is how initiation of antiretroviral treatment should relate
to patients’ readiness and commitment. Although
patients’ readiness is emphasised as a requirement for
starting treatment in several guidelines,1–4 the guidelines
are neither clear nor in consensus about what
constitutes readiness and how this readiness should be
assessed. Given this ambiguity, readiness may be used to
ration resources, particularly in resource poor settings,
in which access to antiretrovirals is currently gaining
support. The potential of using readiness to improve
HIV prevention and care outcomes, however, mandates
that we closely examine the use of readiness for starting
highly active antiretroviral treatment (HAART).
Studies about assessing patients’ readiness for
starting HAART or the impact of this on therapeutic
success are few. One small study found that lack of
readiness resulted in interrupted treatment and risky
sexual behaviour; therefore, readiness for treatment
may help care givers to make decisions about when to
start treatment with antiretrovirals for each patient.5
The potential importance of treatment readiness for
therapeutic success is why a more structured and
systematic approach to evaluating readiness is needed.
In addition, a systematic evaluation of the use of treat-
ment readiness becomes particularly important in set-
tings where “readiness” may be misused to ration
resources. Rigorously collected data will be critical in
shaping appropriate interventions that go beyond
anecdotal notions that readiness is important in deter-
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Clinical indicators have been central to debates on
when to initiate HAART, where CD4 cell count is a key
determining factor.6–9 By incorporating a compulsory
drug readiness programme into decisions on starting
treatment, the South African government’s HAART
rollout plan expands this debate.10 The South African
plan is fairly detailed and specific in requiring education
on HIV/AIDS, positive living, opportunistic infections,
care and treatment for HIV/AIDS, HAART side effects,
and the importance of treatment adherence. Although
early in its implementation, the South African HAART
rollout plan not only expands the debate on when to
initiate therapy, but may also provide an opportunity to
understand and evaluate the benefit of treatment readi-
ness for decisions on HAART initiation.
What are possible ways of understanding and
ascertaining patients’ readiness for starting HAART?
Intuitively, we would expect there to be a range of lev-
els for readiness depending, among other things, on
disease state, knowledge and understanding of anti-
retrovirals, levels of stigma and discrimination, sex,
existing support structures, and motivation. Given the
complex set of factors that are likely to influence readi-
ness, what minimum level of readiness should
distinguish between decisions to start or delay
treatment? Using the South African HAART rollout
plan as a point of departure, we present a framework
for how readiness may be understood and suggest a
possible method that may help in measuring readiness.
What constitutes adequate readiness to
start HAART?
One way of considering and distinguishing between
different levels of treatment readiness is to think in
terms of variations of health literacy, including three
broad categories—basic, functional, and critical lit-
eracy.11 12 Within this context, readiness can range from
knowledge of basic information about antiretroviral
treatment to a more comprehensive approach that
empowers patients not only to understand the
fundamentals involved in participating in treatment
but also includes the social skills and capacity to effec-
tively access other pertinent health services and main-
tain good health. Using these three categories as a
foundation, box 1 gives a framework for understanding
HAART treatment readiness.
In box 1, we have distinguished between the
minimum readiness before starting treatment (basic)
and the levels of readiness that may result from having
treatment (functional and critical readiness). Readiness
is also likely to be influenced by personal and social
factors. For example, someone who has the support of
family or friends and the personal drive to participate
in treatment, but who does not have the basic informa-
tion to start treatment, will have a different set of needs
before becoming ready than someone who may have
the information but lacks personal will and social sup-
port to participate in treatment. In this context, prepar-
ing the person with the information deficit is less
challenging. In other words, what constitutes readiness
for starting treatment should take all of these elements
into account. Although we have given a somewhat
polarised example, there can be different levels of
knowledge, personal initiative, social support, etc. The
readiness required to start treatment is also likely to be
different from the readiness required to maintain suc-
cessful participation in antiretroviral treatment pro-
grammes in an individual’s lifetime. In addition,
interactions with patients and care givers may also
affect thinking and action about readiness—and, more
importantly, the interface between patients and care
givers is likely to influence whether patients maintain
long term readiness for HAART after starting. The
process of building patients’ readiness, therefore, must
be supportive and encouraging.
After participation in a drug-readiness pro-
gramme, patients should fulfil at least the criteria listed
under basic readiness. The functional and critical levels
of readiness may precede starting treatment or may be
attained at various points in the course of treatment
Box 1: Readiness to start drug treatment
Before starting
Basic
• Basic knowledge of HIV transmission and
prevention
• Understanding of antiretroviral treatment, the side
effects of treatment, and belief in treatment efficacy
• Ability to comprehend, cope, and comply with
prescribed actions, such as treatment adherence and
safer sexual practices
• Willingness to create support systems to cope with
HIV status and facilitate treatment, such as disclosing
status to family, friends, and partners
After starting
Functional
• Advanced knowledge and skills to cope and manage
HIV status and treatment that is grounded on
experiences
• Ability to recognise and seek care for opportunistic
infections
Critical
• Considerable level of knowledge, personal
autonomy, skills, and confidence to manage the
consequences of HIV status and treatment
• Capacity to take action that encourages health and
discourages the determinants of ill health, such as
substance abuse, unsafe sexual practice, and adherence
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and will vary among people, but every effort should be
made to move people forward through active collabo-
ration with community organisations, non-state run
programmes, and other sources of support.
Box 2 shows the factors that constitute basic treat-
ment readiness. Based on factors that have been used
to assess readiness for behavioural changes, readiness
for HIV treatment may include an understanding of
the need for treatment, drive to live, and knowledge
and capacity to maintain and build on
commitment.13–15 Personal responsibilities over these
categories may differ by sex and age group, but what
constitutes readiness should remain consistent. Chil-
dren and young adolescents or adults with mental dis-
abilities may not completely understand the conse-
quences of their illness or the expected commitment
required for treatment initiation and maintenance and
will therefore require a care giver to support them dur-
ing treatment. Care providers of HIV infected children
should, therefore, participate in the drug readiness
programme. Adolescents may or may not require a
care giver or parent to participate for them to enrol in
treatment, although it would be more beneficial.
Can readiness to start HAART be
measured?
To date, a few small studies have measured readiness to
start treatment using MEMS (medication event
monitoring systems).16 This strategy has use for
measuring drug adherence but is inadequate for
assessing the broader concept of readiness. Experience
garnered in assessing readiness in substance abuse
treatment programmes,17–20 despite considerable differ-
ences between the needs of the people in such
programmes and patients starting HIV treatment,
gives some important principles for assessing readi-
ness for HIV treatment. Both groups, for example, face
challenges with incorporating life changes and coping
with their diagnosis that require high levels of long
term commitment for success. Substance misuse
programmes have used psychometric assessment
scores to assess readiness. Based on basic readiness for
treatment with antiretrovirals, as outlined in box 2, it is
feasible to develop and test the reliability of
psychometric measures. Importantly, operational
research that monitors and measures the relationship
between readiness and treatment outcomes is critical.
As the World Health Organization and UNAIDS’s
“3 by 5” initiative takes shape (to give three million
people with HIV/AIDS in low and middle income
countries antiretroviral treatment by the end of 2005),
and as nations with limited resources increase access to
HIV treatment, understanding and measuring readi-
ness may become useful for HIV prevention and treat-
ment outcomes. However, countries should be cautious
about using readiness to ration access to treatment.
Importantly, the assessment of readiness needs to be
viewed as a process to advance all patients to a level of
readiness that will support starting treatment and
ensure equitable access to therapy. Developing sound
criteria without restricting access to treatment is a chal-
lenging task that is integrally linked to the definition
and measurement of readiness for treatment. The
South African plan gives a valuable point of departure
beyond the existing anecdotal notions that readiness is
important in determining when to start HAART. We
have presented a potential way forward in understand-
ing how to construct, measure, and unpack the poten-
tial benefits of readiness for HIV prevention and
treatment outcomes, but rigorous tools are required to
assess various constructs of readiness.
We thank Motshedisi Sebitloane, department of medicine at the
University of KwaZulu-Natal, and Jerome Singh, Centre for
AIDS Programme of Research in South Africa.
Contributors and sources: The idea for the manuscript grew out
of collaborative discussions on patient and provider challenges
facing the South African HAART rollout plan. HTG searched
the literature and drafted and revised the manuscript. KPM and
QAK contributed to drafting and revising the manuscript. QAK
gave additional guidance and direction for the paper. HTG is
guarantor.
Funding: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, US Department of Health and
Human Services (1U19AI51794), and Research Supplement for
Under-represented Minorities to the Brown/Tufts/Lifespan,
Center for AIDS Research, Brown University, Providence,
Rhode Island (P30 AI42853-05S1).
Competing interests: None declared.
Box 2: Basic readiness
Need
The person initiating treatment must understand that treatment can extend
health and productive life. The participants must trust that treatment will be
helpful. This is one of the factors that could be bolstered by experience on
treatment.
Drive to live
This desire may be supported or discouraged by other aspects in life
(family, children, partners, and friends). A component of the drive to live
should include an assessment of shame, stigma, and how perceived or
experienced discrimination is a force in the person’s life. Understanding a
person’s drive to live may be guided by their expressions of fear for death.
Within this context, assessing the presence and magnitude of anger,
depression, and other emotionally distressing elements could be useful.
Capacity
Knowledge about HIV prevention and transmission and basic knowledge
about the process of treatment and how treatment works, including side
effects, is essential. A basic understanding that treatment works by “reducing
the virus” in the body and the need to maintain viral suppression. Patients
should understand the importance of adherence to treatment and safe
sexual practice. Patients need confidence in their ability to meet
expectations of commitment to treatment, including the coping strategies to
maintain emotional stability.
Summary points
No clarity or consensus exists on what constitutes
patients’ readiness for HIV treatment and how
readiness should be assessed
The more established and readily measurable
criteria currently used in decisions to start highly
active antiretroviral treatment (HAART) need to
be expanded
Understanding the use of treatment readiness is
particularly critical in settings where its role in
initiating therapy may be misused to ration
resources
Education and debate
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Achieving food security in vulnerable populations
Deborah Cohen
Communities who rely on raising livestock are most vulnerable to hunger when drought or other
disaster strikes. How can aid organisations provide effective help?
Hunger and malnutrition cause tremendous human
suffering and cost developing countries billions of dol-
lars in lost productivity and national income. The
number of hungry people in the world rose to 852 mil-
lion between 2000 and 2002, up by 18 million from the
mid-1990s, and the total number of hungry people in
sub-Saharan Africa is 203 million, a third of the popu-
lation.1 The human and economic costs of hunger will
increase if the trend is not reversed. I visited northwest
Kenya to see how organisations work to try to improve
food security in pastoralist communities.
Food security
The 2004 annual report from the Food and
Agriculture Organization says that little is done
globally to fight hunger, although the resources
needed to combat it are small compared with the ben-
efits.1 Every dollar invested in reducing hunger can give
from five to over 20 times as much in benefits. The
report recommends giving priority to actions to
improve food security.1
But food security is a complex issue. A country or
region is food secure when: “All people, at all times,
have both physical and economic access to sufficient
food to meet their dietary needs for a healthy and pro-
ductive life.”2 Food security depends principally on
three variables: availability of food, access to food and a
nutritious diet, and proper use of food to ensure maxi-
mal nutrition and hygiene.3 In turn, each of these vari-
ables is influenced by several factors, the most
important of which is poverty; others include the
national and international economic environment,
population growth, infrastructure, the climate, the level
of investment and donor commitment, access to
appropriate training and job skills, asset base, conflict
and access to pasture, and the quality of diet, health,
and sanitation.
Because of the number of influencing factors, a
multilateral approach involving both the international
community and national governments is needed.
Some factors, such as economic conditions and
infrastructure, are the responsibility of national
governments and the international community as a






















775BMJ VOLUME 331 1 OCTOBER 2005 bmj.com
 on 5 October 2005 bmj.comDownloaded from 
